Shionogi launches Fectcroja in the UK for aerobic Gram-negative bacteria infections

Shionogi has announced the launch of its new antibiotic in the UK for the treatment of infections due to aerobic Gram-negative bacteria in patients over 18 with limited treatment options. 

The UK is the first country to launch Fetcroja (cefiderocol), which is the first treatment to provide coverage against all Gram-negative pathogens that the World Health Organization feels are a critical priority. 

Image caption:  Photo by hiromitsu morimoto

read more